Alkermes plc
As of Oct 22, 2026, Alkermes is in Stage 3, the topping phase, now in week 6 (since Sep 16, 2026). It closed at $44.18, 20.0% below its 52-week high and above its 200-day average, which is rising.
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the… More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is ALKS early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
ALKS among Drug Manufacturers - Specialty & Generic17th of 84 by relative strength
All 84 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | CPIX | Stage 2 · wk 23 | 98 | +6.8% |
| 2 | ETON | Stage 2 · wk 30 | 97 | −10.1% |
| 3 | ANIK | Stage 2 · wk 15 | 96 | +3.5% |
| 4 | IRWD | Stage 3 · wk 3 | 96 | −16.4% |
| 5 | TEVA | Stage 2 · wk 9 | 95 | +3.1% |
| 6 | AMRX | Stage 2 · wk 19 | 95 | +5.9% |
| 7 | KNSA | Stage 2 · wk 73 | 95 | +6.2% |
| 8 | AMLX | Stage 2 · wk 15 | 93 | −6.6% |
| …17 | ALKS | Stage 3 · wk 6 | 82 | +4.9% |
Alkermes: quick answers
What stage is Alkermes in?
As of Oct 22, 2026, Alkermes (ALKS) is in Stage 3, the topping phase. It entered Stage 3 on Sep 16, 2026 and is in week 6. What the four stages mean
Is Alkermes in an uptrend?
Its uptrend has stalled. Alkermes is in Stage 3, the topping phase that follows an advance. It trades 10.4% above its 200-day average, which is rising.
How far is Alkermes from its 52-week high?
Alkermes closed at $44.18 on Oct 22, 2026, 20.0% below its 52-week high of $55.22. Its 52-week low is $27.20.
How has Alkermes performed over the past year?
As of Oct 22, 2026, Alkermes is up 40.5% over the past year and up 56.3% so far in 2026.
Which sector and industry is Alkermes in?
Alkermes is in the Drug Manufacturers - Specialty & Generic industry, part of the Health Care sector.
About this companyHealth Care· Drug Manufacturers - Specialty & Generic
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.